Hamad Medical Corporation at IDWeek 2026

Oct 21–24, 2026 Washington, DC ~12k attendees Website

Hamad Medical Corporation brings 2 presentations to IDWeek 2026 in Washington. Its program spans treatment of drug-resistant infections and tuberculosis diagnosis. It reports outcomes of intravenous fosfomycin for multidrug-resistant Gram-negative infections and how useful TB PCR is when smear tests are negative.

OrganizationIDWeek 2026 Attendance
Poster
Thu Oct 22
12:15pm–1:30pm
Clinical Outcomes of Intravenous Fosfomycin in Managing Multidrug-Resistant Gram-Negative Infections: Insights from a Matched Cohort Study
Poster Hall B-C · Poster P-140
A4. Treatment of antimicrobial resistant infections
Poster
Fri Oct 23
12:15pm–1:30pm
The utility of TB PCR in evaluation of smear negative pulmonary TB i, a 5-year evaluation study in Qatar
Poster Hall B-C · Poster P-1302
K. Tuberculosis and other Mycobacterial Infections

Explore the full IDWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Washington. Leave your work email and we’ll be in touch.

Privacy

Download the full IDWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Hamad Medical Corporation

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction